|
Eribulin ORA: A novel oral formulation of eribulin based on combination with the P-gp inhibitor HM30181A. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Athenex |
Research Funding - Athenex |
|
|
|
|
Stock and Other Ownership Interests - Athenex |
Patents, Royalties, Other Intellectual Property - Athenex |
|
|
|
Stock and Other Ownership Interests - Athenex; Merck Sharp & Dohme |
|
|
|
|
Stock and Other Ownership Interests - Athenex |
Patents, Royalties, Other Intellectual Property - Athenex |
|
|
|
Stock and Other Ownership Interests - Athenex |
Patents, Royalties, Other Intellectual Property - Athenex |